On May 11, 2020 Netflix released a controversial documentary to its 190 million global subscriber base.
The film, Have A Good Trip: Adventures In Psychedelics, featured celebrities detailing their personal experiences with psychedelic drugs.
Have A Good Trip soared to the top of Netflix’s viewing charts and stayed there.
Although Netflix doesn’t reveal viewership data on individual titles, FlixPatrol, a site which compiles data on Netflix’s Top 10 most viewed list, says Have A Good Trip held a spot in the streaming giant’s most-viewed content for 16 days.
The film also earned feature reviews in a number of large media outlets including Variety, The Guardian, and the New York Times.
Although reviews for the merits of A Good Trip as entertainment were mixed, Arstechnica summed up the film’s high-profile debut importance as, “A gateway drug to de-stigmatizing psychedelics.”
In the months which followed the release of the documentary, psychedelics have pushed further into the mainstream with backing by medical researchers and some of Silicon Valley’s most successful investors.
The medicinal potential of psychedelics has reached mainstream medical research publications as well. For example, the Journal of Palliative Medicine has stated, “Psychiatric research in the 1950s and 1960s showed potential for psychedelic medications to markedly alleviate depression and suffering associated with terminal illness. A single or brief series of sessions often results in substantial and sustained improvement among people with treatment-resistant depression and anxiety.”
Medicinal psychedelics are quickly becoming serious business. To date, investors backed a number of leading psychedelics companies conducting research and clinical trials aimed at unlocking psychedelics’ inherent medicinal potential for many chronic conditions. These companies include COMPASS Pathways (NASDAQ:CMPS), Field Trip Health (CSE:FTRP) (OTC:FTRPF), Cybin Inc. (NEO:CYBN) (OTC:CLXPF), and Numinus Wellness (TSXV:NUMI) (OTC:LKYSF).
The rapid rise of these companies has helped propel psychedelics into the mainstream in 2020 and, based on some recent developments in the sector, the trend of increasing acceptance and interest in psychedelics is will continue into 2021.
The first psychedelic sector development came from Mount Sinai Hospital, the hospital ranked 14th in the United States by U.S. News & World Report.
On January 7, 2021 Mount Sinai Hospital revealed it will be opening The Center for Psychedelic Psychotherapy and Trauma Research.
The Center will pursue “a multipronged clinical and research approach to discovering novel and more efficacious therapies…